Eli Lilly stock, live, through the tokenised share

Signals, right now

Manufacturing capacity is the constraint, not demand

For the incretin drugs that drive this company's valuation, the question has not been whether people want them but whether enough can be made. Capital spending announcements and plant approvals therefore move the share in a way that would be strange for most pharmaceutical companies. A supply headline here is a revenue headline.

Reimbursement decides how big the market actually is

A drug that works is not the same as a drug that is paid for. Coverage decisions by insurers and national health systems set the realistic ceiling on volume, and they are made slowly, publicly and politically. Much of the argument about this share price is really an argument about those decisions rather than about the medicine.

The dividend exists, and this token probably does not pass it on

Lilly pays a dividend. A backed token generally does not pass dividends through unless the issuer's terms say so, which changes the total return materially over anything longer than a few weeks. Read the issuer's terms before treating the token as equivalent to the shareholding.

The part we cannot verify

We read the token's price, its traded volume and the value of tokens in issue. We do not audit the custody behind it. The price was checked against the exchange's last close when this page was built and agreed to within half a percent. For the official price, use the exchange or a broker.